FDA approval: Alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib

Clinical Cancer Research

Volumn 22, Issue 21, 2016, Pages 5171-5176

  Larkins, Erin ^a   Blumenthal, Gideon M ^a   Chen, Huanyu ^a   He, Kun ^a   Agarwal, Rajiv ^a   Gieser, Gerlie ^a   Stephens, Olen ^a   Zahalka, Eias ^a   Ringgold, Kimberly ^a   Helms, Whitney ^a   Shord, Stacy ^a   Yu, Jingyu ^a   Zhao, Hong ^a   Davis, Gina ^a   McKee, Amy E ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALECTINIB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CRIZOTINIB; TYROSINE KINASE RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AGED; ANAPLASTIC CARCINOMA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MYALGIA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; DRUG APPROVAL; LUNG TUMOR; METABOLISM; PROCEDURES; UNITED STATES;

ASPARTATE AMINOTRANSFERASES; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84994207040     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1293     Document Type: Article

References (31)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-7.
2. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008; 105:19893-7.
3. Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS One 2014; 9: e100866.
4. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8:823-59.
5. USPI crizotinib (issue date August 2011) [PDF on the Internet]; 2011 [cited 2016 Apr 5]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202570s000lbl.pdf.
6. USPI crizotinib (revision date November 2013) [PDF on the Internet]; 2013 [cited 2016 Apr 5]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202570s006lbl.pdf.
7. Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20:2029-34.
8. Esfahani K, Agulnik JS, Cohen V. A systematic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. Front Oncol 2014; 4:174.
9. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4:120ra17.
10. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18:1472-82.
11. Costa DB, Shaw AT, Ou SI, Solomon BJ, Riely GJ, Ahn M, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33:1881-8.
12. USPI ceritinib (issue date April 2014) [PDF on the Internet]; 2015 [cited 2016 Apr 5]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205755lbl.pdf.
13. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 2015; 21: 2436-9.
14. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Chemistry review(s); 2015 [cited 2016 Feb 9]; [45 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/208434Orig1s000ChemR.pdf. Files updated daily.
15. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Pharmacology review(s); 2015 [cited 2016 Apr 18]; [154 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/208434Orig1s000PharmR.pdf. Files updated daily.
16. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s); 2015 [cited 2016 Apr 11]; [81 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/208434Orig1s000ClinPharmR.pdf. Files updated daily.
17. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) [about 13 screens] [cited 2016 Jun 20]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
18. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, et al. Challenges relating to solid tumor brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013; 14:e396-406.
19. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Medical review(s); 2015 [cited 2016 Apr 8]; [127 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/208434Orig1s000MedR.pdf Files updated daily.
20. Pasternak RC, Smith SCJr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:567-72.
21. Nokihara H, Hida T, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. J Clin Oncol 34, 2016 (suppl; abstr 9008).
22. Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: a US Food and Drug Administration trial-level and patient-level analysis. J Clin Oncol 2015; 33:1008-14.
23. Guidance for industry: clinical trial endpoints for the approval of nonsmall cell lung cancer drugs and biologics [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Apr 15]. Available from: http://www.fda.gov/downloads/Drugs/⋯/Guidances/UCM259421.pdf
24. Sorenson JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6:1474-80.
25. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-705.
26. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865-72.
27. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242:882-8.
28. Solomon BJ, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:2167-77.
29. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014; 74:1023-8.
30. Inoue A, Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, et al. One-year follow-up of a phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2013; 8:S1204 (abstract P3.11-034).
31. Gadgeel S, Ou S, Chiappori AA, Riely G, Lee R, Garcia L, et al. Aphase1dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028). J Thorac Oncol 2013; 8: S199 (abstract O16.06).